302 related articles for article (PubMed ID: 21543626)
1. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
Galsky MD; Chen GJ; Oh WK; Bellmunt J; Roth BJ; Petrioli R; Dogliotti L; Dreicer R; Sonpavde G
Ann Oncol; 2012 Feb; 23(2):406-10. PubMed ID: 21543626
[TBL] [Abstract][Full Text] [Related]
2. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
[TBL] [Abstract][Full Text] [Related]
4. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
Sonpavde G; Watson D; Tourtellott M; Cowey CL; Hellerstedt B; Hutson TE; Zhan F; Vogelzang NJ
Clin Genitourin Cancer; 2012 Mar; 10(1):1-5. PubMed ID: 22340630
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
6. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
[TBL] [Abstract][Full Text] [Related]
7. Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
Freshwater T; Li H; Valiathan C; Li M; Perini R; Bracco OL; Frenkl T; Keefe S
Am J Clin Oncol; 2019 Oct; 42(10):802-809. PubMed ID: 31503064
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
11. Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma.
Richters A; Kiemeney LALM; Mehra N; Westgeest HM; Birtle A; Bryan RT; Aben KKH
Clin Genitourin Cancer; 2022 Aug; 20(4):e346-e352. PubMed ID: 35039230
[TBL] [Abstract][Full Text] [Related]
12. Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis.
Mori K; Schuettfort VM; Yanagisawa T; Katayama S; Pradere B; Laukhtina E; Rajwa P; Mostafaei H; Sari Motlagh R; Quhal F; Moschini M; Soria F; Teoh JYC; D'Andrea D; Abufaraj M; Albisinni S; Krajewski W; Egawa S; Karakiewicz PI; Rink M; Shariat SF;
Eur Urol Focus; 2022 Nov; 8(6):1687-1695. PubMed ID: 35279408
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with carboplatin and methotrexate in the treatment of advanced urothelial carcinoma. A phase II study.
Dogliotti L; Bertetto O; Berruti A; Clerico M; Fanchini L; Sicora W; Faggiuolo R
Am J Clin Oncol; 1995 Feb; 18(1):78-82. PubMed ID: 7847264
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
[TBL] [Abstract][Full Text] [Related]
17. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
18. Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.
Gravis G; Billon E; Baldini C; Massard C; Hilgers W; Delva R; Walz J; Pignot G; Rybikowski S; Dermeche S; Thomassin J; Brunelle S; Lavaud P; Loriot Y;
Eur J Cancer; 2018 Nov; 104():236-238. PubMed ID: 30316610
[No Abstract] [Full Text] [Related]
19. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A; Boni L; Tiseo M; Fossella FV; Schiller JH; Paesmans M; Radosavljevic D; Paccagnella A; Zatloukal P; Mazzanti P; Bisset D; Rosell R;
J Natl Cancer Inst; 2007 Jun; 99(11):847-57. PubMed ID: 17551145
[TBL] [Abstract][Full Text] [Related]
20. [A Study on the Number of Cycles of First-Line Chemotherapy for Advanced Urothelial Carcinoma].
Takagi K; Kawase K; Minoshima K; Yamaha M; Horie M
Hinyokika Kiyo; 2020 Jul; 66(7):217-220. PubMed ID: 32723975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
